In this study, we examine the cost effectiveness of carvedilol for the treatment of chronic heart failure (CHF).
We use a Markov model to project life expectancy and lifetime medical care costs for a hypothetical cohort of patients with CHF who were assumed alternatively to receive carvedilol plus conventional therapy (digoxin, diuretics, and angiotensin-converting enzyme inhibitors) or conventional therapy alone.
Patients on carvedilol were assumed to experience a reduced risk of death and hospitalization for CHF, which is consistent with findings from the US Carvedilol Heart Failure Trials Program.
The benefits of carvedilol were projected under 2 alternative scenarios.
In the first ( « limited benefits »), benefits were conservatively assumed to persist for 6 months, the average duration of follow-up in these clinical trials, and then end abruptly.
In the other ( « extended benefits »), they were arbitrarily assumed to persist for 6 months and then decline gradually over time, vanishing by the end of 3 years.
We estimated our model using data from the US Carvedilol Heart Failure Trials Program and other i sources.
For patients receiving conventional therapy alone, estimated life expectancy was 6.67 years ; corresponding figures for those also receiving carvedilol were 6.98 and 7.62 years under the limited and extended benefits scenarios, respectively. (...)
Mots-clés Pascal : Insuffisance cardiaque, Carvédilol, Bloquant bêta-adrénergique, Analyse coût efficacité, Economie santé, Chimiothérapie, Traitement, Efficacité traitement, Homme, Vasodilatateur, Appareil circulatoire pathologie, Cardiopathie
Mots-clés Pascal anglais : Heart failure, Carvedilol, Beta blocking agent, Cost efficiency analysis, Health economy, Chemotherapy, Treatment, Treatment efficiency, Human, Vasodilator agent, Cardiovascular disease, Heart disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0196469
Code Inist : 002B02F04. Création : 16/11/1999.